Article citationsMore>>

Boye, K., Jebsen, N.L., Zaikova, O., Knobel, H., Londalen, A.M., Trovik, C.S., Monge, O.R. and Hall, K.S. (2017) Denosumab in Patients with Giant-Cell Tumor of Bone in Norway: Results from a Nationwide Cohort. Acta Oncologica, 56, 479-483.

has been cited by the following article:

• TITLE: Clinical Case: Treatment of a Giant Cells Tumor of the Proximal Femur in a Disadvantaged Area

  AUTHORS: M. Sawadogo, S. Ouedraogo, A. Korsaga, S. Tinto, A. J. I. Ouedraogo, H. Kafando, S. Ouedraogo, M. Tall, S. C. Da

  KEYWORDS: Giant Cell Tumor, Femoral Neck, Great Trochanter, Curettage, Denosumab

  JOURNAL NAME: Open Journal of Orthopedics, Vol.7 No.11, November 9, 2017

  ABSTRACT: There have been not many reports on the result of intralesional excision for giant cell tumors (GCTs) of the great trochanter and femoral neck because of its rarity. The authors present the case of a 35-year-old female patient managed with intralesional curettage and filling the defect with autologous bone graft from iliac crest. An appoint of three doses of Denosumab was done postoperatively. The article discusses the clinical aspects and surgical treatment, and the benefits of Denosumab. This report aimed to demonstrate the possibility to perform curetage for giant cell tumor of the hip even the recommandation for this location is wide resection and endoprothesis fixation.